

FINAL TERMS
(“Final Terms”)

for loan no. 5
under Swedish Orphan Biovitrum AB (publ)’s (the “Company”)
Swedish MTN Programme

The General Terms and Conditions dated 26 April 2024 together with the Final Terms set forth below shall apply to the Loan. Unless otherwise stated, definitions used in these Final Terms are set forth in the Terms and Conditions or otherwise in the Company’s base prospectus, approved and registered with the Swedish Financial Supervisory Authority on 26 April 2024 (the “**Base Prospectus**”) including any published supplemental prospectus prepared for the MTN Programme from time to time in accordance with Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (the “**Prospectus Regulation**”). This document constitutes the Final Terms for the Loan and has been prepared in accordance with Article 8 of the Prospectus Regulation.

Complete information about the Company and the MTN Programme can only be obtained through the Base Prospectus, any published supplementary prospectuses and these Final Terms, which is why investors who are considering investing in MTN should read these documents together and in full. The Base Prospectus and any supplementary prospectuses to the Base Prospectus as applicable are available on the Company’s website www.sobi.com.

GENERAL

- | | | |
|-----|----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. | Loan number: | 5 |
| | (i) Tranche name: | 1 |
| 2. | Aggregate Nominal Amount: | |
| | (i) for the loan: | SEK 1,150,000,000 |
| | (ii) for tranche 1: | SEK 1,150,000,000 |
| 3. | Price per MTN: | 100.00 % of the Nominal Amount |
| 4. | Currency: | SEK |
| 5. | Nominal Amount: | SEK 1,250,000 |
| 6. | Loan Date: | 19 November 2024 |
| 7. | Interest Commencement Date: | Loan Date |
| 8. | Settlement Date: | Loan Date |
| 9. | Maturity Date: | 19 November 2026 |
| 10. | Voluntary redemption of MTN | Applicable |
| | | The issuer may redeem all, but not some only, of the MTN in full: |
| | | (i) at any time from and including the first Business Day falling one (1) months prior to the Maturity Date to, but excluding, the Maturity Date, at an amount equal to 100 per cent. of the Nominal Amount together with accrued but unpaid interest |
| 11. | Basis for calculation of interest: | Floating Rate (FRN) |
| 12. | Amount as basis for calculation of interest | Nominal Amount |

BASIS FOR CALCULATION OF RETURN

- | | | |
|-----|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 13. | Fixed Rate: | Not applicable |
| 14. | Floating Rate (FRN): | Applicable |
| | (i) Base Rate: | 3 months STIBOR |
| | (ii) Margin: | + 0.90 % annual interest calculated on Nominal Amount |
| | (iii) Interest Determination Date: | Two Business Days before each Interest Period, the first time on 15 November 2024 |
| | (iv) Interest Period: | The time from 19 November 2024 up to and including 19 February 2025 (the first Interest Period) and thereafter each period of approx. 3 months with the end date on an Interest Payment Date. |
| | (v) Interest Payment(s): | The final day in each Interest Period, the 19 February, the 19 May, the 19 August and the 19 November, the first time on 19 February 2025 and the last time on the Maturity Date. |
| | (vi) Day Count Convention Method: | Actual/360 |
| | (vii) Risk factors: | In accordance with the risk factor with the heading “ <i>Risks relating to interest rate constructions</i> ” in the Base Prospectus. |
| 15. | Zero Coupon: | Not applicable |

REPAYMENT

- | | | |
|-----|------------------------------------------------------------------|-------------------------|
| 16. | Amount at which MTN is to be repaid on the Maturity Date: | 100 % of Nominal Amount |
|-----|------------------------------------------------------------------|-------------------------|

OTHER

- | | | |
|-----|------------------------------------------------------------------|--------------------------------------------------------------|
| 17. | Estimated net proceeds | SEK 1,150,000,000 less customary transaction costs and fees. |
| 18. | Use of net proceeds | General corporate purposes |
| 19. | Admission to trading on a Regulated Market: | Applicable |
| | (i) Regulated Market: | Nasdaq Stockholm |
| | (ii) Estimated total costs associated with admission to trading: | SEK 45,000 |
| | (iii) Total number of securities admitted to trading: | 920 |
| | (iv) Earliest date for admission to trading: | 19 November 2024 |
| 20. | Interests: | Not applicable |
| 21. | Credit rating for Loans: | Not applicable |
| 22. | Resolutions as basis of the issue: | Not applicable |
| 23. | Information from third parties: | Not applicable |

24. **Issuing Agent:**
(i) for tranche 1: Danske Bank A/S, Danmark, Sverige Filial and Svenska Handelsbanken AB (publ)
25. **Administrative Agent:** Svenska Handelsbanken AB (publ)
26. **ISIN:** SE0013885308

The Company confirms that the above Final Terms are applicable to the Loan, together with the General Terms and Conditions, and undertakes, in accordance therewith, to repay the Loan and to pay interest in accordance herewith.

The Company further confirms that any material event after the date of the Base Prospectus that could affect the market's assessment of the Loan and the Company to this MTN have been publicly disclosed.

Stockholm 14 November 2024

SWEDISH ORPHAN BIOVITRUM AB (PUBL)